Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

NIR-II Aza-BODIPY Dyes Bioconjugated to Monoclonal Antibody Trastuzumab for Selective Imaging of HER2-Positive Ovarian Cancer

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • Contributors:
      Institut de Chimie Moléculaire de l'Université de Bourgogne Dijon (ICMUB); Université de Bourgogne (UB)-Institut de Chimie - CNRS Chimie (INC-CNRS)-Centre National de la Recherche Scientifique (CNRS); Institute for Advanced Biosciences / Institut pour l'Avancée des Biosciences (Grenoble) (IAB); Centre Hospitalier Universitaire CHU Grenoble (CHUGA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang - Auvergne-Rhône-Alpes (EFS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA); Laboratoire d'Immunologie et d'Immunothérapie des cancers Dijon (LIIC); École Pratique des Hautes Études (EPHE); Université Paris Sciences et Lettres (PSL)-Université Paris Sciences et Lettres (PSL)-Université de Bourgogne (UB)-Université Bourgogne Franche-Comté COMUE (UBFC); Centre Hospitalier Universitaire CHU Grenoble (CHUGA); Institut universitaire de France (IUF); Ministère de l'Education nationale, de l’Enseignement supérieur et de la Recherche (M.E.N.E.S.R.); Federal Institute for Materials Research and Testing - Bundesanstalt für Materialforschung und -prüfung (BAM); ANR-18-CE18-0012,WazaBY,Développement de plateformes aza-BODIPY pour la construction d'agents multimodaux et de sondes thérapeutiques traçables(2018)
    • بيانات النشر:
      CCSD
      American Chemical Society
    • الموضوع:
      2023
    • Collection:
      EPHE (Ecole pratique des hautes études, Paris): HAL
    • نبذة مختصرة :
      International audience ; Using fluorescence guided surgery (FGS) to cytoreductive surgery helps achieving complete resection of microscopic ovarian tumors. The use of visible and NIR-I fluorophores has led to beneficial results in clinical trials; however, involving NIR-II dyes seems to outperform those benefits due to the deeper tissue imaging and higher signal/noise ratio attained within the NIR-II optical window. In this context, we developed NIR-II emitting dyes targeting HER2-positive ovarian tumors, by coupling water-soluble NIR-II aza-BODIPY dyes to the FDA approved anti-HER2 antibody, namely trastuzumab. These bioconjugated NIR-II-emitting dyes displayed a prolonged stability in serum, and a maintained affinity towards HER2 in vitro. We obtained selective targeting of HER2 positive tumors (SKOV-3) in vivo, with a favorable tumor accumulation. We demonstrated the fluorescence properties and the specific HER2 binding of the bioconjugated dyes in vivo, and thus their potential for NIR-II FGS in the cancer setting.
    • Relation:
      info:eu-repo/semantics/altIdentifier/pmid/36996803; PUBMED: 36996803
    • الرقم المعرف:
      10.1021/acs.jmedchem.3c00100
    • الدخول الالكتروني :
      https://hal.science/hal-04091996
      https://hal.science/hal-04091996v1/document
      https://hal.science/hal-04091996v1/file/Godard-mainFile-rev2.pdf
      https://doi.org/10.1021/acs.jmedchem.3c00100
    • Rights:
      info:eu-repo/semantics/OpenAccess
    • الرقم المعرف:
      edsbas.92E196EB